PENTIXAPHARM HOLDING N AG Cash Flow Conversion Efficiency
PENTIXAPHARM HOLDING N AG cash flow conversion efficiency. Based on the latest financial reports, PENTIXAPHARM HOLDING N AG (PTP) has a cash flow conversion efficiency ratio of -0.090x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.57 Million ≈ $-3.01 Million USD) by net assets (€28.47 Million ≈ $33.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of PENTIXAPHARM HOLDING N AG (2021–2025)
Cash flow conversion efficiency of PENTIXAPHARM HOLDING N AG from 2021 to 2025. This chart illustrates how PENTIXAPHARM HOLDING N AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of PENTIXAPHARM HOLDING N AG for real-time trading data and today's change.
PENTIXAPHARM HOLDING N AG Cash Flow Conversion Ratio Explained
PENTIXAPHARM HOLDING N AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
PENTIXAPHARM HOLDING N AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PENTIXAPHARM HOLDING N AG ranked by their cash flow conversion efficiency. Also see PENTIXAPHARM HOLDING N AG market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Identillect Technologies Corp
V:ID
|
0.006x |
|
Pacific Bay Minerals Ltd
V:PBM
|
0.110x |
|
2CUREX AB SEK-10
F:2QE
|
N/A |
|
Corero Network Security plc
LSE:CNS
|
-0.046x |
|
Alveen
PA:MLALV
|
N/A |
|
Tlou Energy Ltd
AU:TOU
|
-1.918x |
|
Ribbon Acquisition Corp Rights
NASDAQ:RIBBR
|
N/A |
|
Cake Box Holdings PLC
LSE:CBOX
|
0.245x |
Annual Cash Flow Conversion Efficiency for PENTIXAPHARM HOLDING N AG (2021–2025)
The table below shows the annual cash flow conversion efficiency of PENTIXAPHARM HOLDING N AG from 2021 to 2025. Review PTP free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €35.07 Million ≈ $41.00 Million |
€-17.97 Million ≈ $-21.01 Million |
-0.512x | -485.10% |
| 2024-12-31 | €49.41 Million ≈ $57.77 Million |
€-4.33 Million ≈ $-5.06 Million |
-0.088x | -299.63% |
| 2023-12-31 | €48.48 Million ≈ $56.68 Million |
€2.13 Million ≈ $2.49 Million |
0.044x | +176.78% |
| 2022-12-31 | €38.47 Million ≈ $44.97 Million |
€-2.20 Million ≈ $-2.57 Million |
-0.057x | -16.04% |
| 2021-12-31 | €27.88 Million ≈ $32.60 Million |
€-1.37 Million ≈ $-1.61 Million |
-0.049x | -- |
About PENTIXAPHARM HOLDING N AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunologic… Read more